Top Trends & Commercial Prospects of Rx-to-OTC Switching Discusses by CBR Pharma in Its Topical Study Available at MarketPublishers.com29 Nov 2017 • by Natalie Aster
LONDON – “Rx-to-OTC switching” is a processes, when a drug that was formerly sold as a prescription-only Rx drug is authorised for sale to the general public without prescription. For healthcare providers and patients, OTC products help to reduce medical treatment costs and also provide easier access to drugs, meantime, for PharmaCos, they allow to extend the lifecycle of off-patent drugs by transferring them to the consumer environment, thus, facilitating renewed revenue growth.
On the basis of overall revenue, the OTC pharmaceutical market has been led by 4 main sectors: cold, allergy and cough; dermatologicals; gastrointestinals; and analgesics. These sectors used to dominate the OTC drugs market during the last 2 decades in terms of volume and revenues.
Rx-to-OTC switching is likely to see uptake during the next 5 years, especially in the dermatological, weight control and cold, allergy and cough sectors.
The major barriers to switching comprise the probability for misuse and abuse of drugs, especially for analgesics, resulting in the need to demonstrate safety and clear labeling to regulatory agencies. Lakh of harmonization in OTC processes between various countries also acts as a challenges for companies intending to launch their products across different geographies.
Topical study “Current and Future Trends in Rx-to-OTC Switching with Insight from Key Industry Opinion Leaders” prepared by CBR Pharma Insights presents a comprehensive snapshot of the in-depth insights and opinions from leading experts and KOLs in the field of Rx-to-OTC switching, thus, providing a clear understanding of the top trends and emerging commercial prospects of switching pharmaceuticals. The report includes a discussion of key characteristics of an ideal Rx-to-OTC switching candidate, examines the most recent successful switches, scrutinises the major barriers and drivers of OTC market, outlines future possible trends in Rx-to-OTC switches globally. Besides, it points out the most promising sectors and geographies for switches, comprises relevant info on the competitive landscape in the OTC markets and touches upon the regulatory framework.
Many other topical research studies by this publisher are at hand in the CBR Pharma Insights online page at MarketPublishers.com.